Anaplastic Large Cell Lymphoma and Breast Implants

A Systematic Review

Published In: Plastic and Reconstructive Surgery, v. 127, no. 6, June 2011, p. 2141-2150

Posted on on June 01, 2011

by Benjamin Kim, Carol P. Roth, Kevin C. Chung, V. Leroy Young, Kristin R. Van Busum, Christopher Schnyer, Soeren Mattke

Read More

Access further information on this document at American Society of Plastic Surgeons

This article was published outside of RAND. The full text of the article can be found at the link above.

BACKGROUND: In recent years, there have been growing concerns about a possible association of non-Hodgkin's lymphoma (NHL)-in particular, anaplastic large cell lymphoma (ALCL)-and breast implants. The purpose of this study was to identify and analyze all reported cases of NHL occurring in patients with breast implants. METHODS: We conducted a systematic literature review of reported cases of NHL in patients with breast implants. Publications were identified with a search algorithm, forward searches, and expert nominations. After references were reviewed and assessed for inclusion or exclusion, case-based data were independently abstracted, reconciled, and adjudicated by multiple investigators. The data were then synthesized and analyzed. RESULTS: Of 884 identified articles, only 83 were relevant to NHL involving the breast and 34 were included in our study. Thirty-six cases of NHL in patients with implants were found, of which 29 (81%) were ALCLs. Although detailed clinical information was lacking in many cases, ALCL oftentimes involved the capsule and/or presented as an unexplained seroma or mass, was negative for Anaplastic Lymphoma Kinase (ALK) expression, and had a relatively indolent clinical course when it developed adjacent to a breast implant. CONCLUSIONS: A form of ALCL, which clinically behaves more like the less-aggressive cutaneous form of ALK-negative ALCL rather than the more-aggressive systemic form, may be associated with breast implants. Future research on the epidemiology and biology of this rare disease is clearly needed to better understand its nature.

This report is part of the RAND Corporation External publication series. Many RAND studies are published in peer-reviewed scholarly journals, as chapters in commercial books, or as documents published by other organizations.

The RAND Corporation is a nonprofit institution that helps improve policy and decisionmaking through research and analysis. RAND's publications do not necessarily reflect the opinions of its research clients and sponsors.